Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Neurology·MeSH: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Prevalence
5.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
Frequently asked questions
How many drugs are in development for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating?
BioSniper tracks 1 drug in development for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating across 1 company.
How many clinical trials target Polyradiculoneuropathy, Chronic Inflammatory Demyelinating?
There are 1 clinical trial targeting Polyradiculoneuropathy, Chronic Inflammatory Demyelinating tracked by BioSniper.
What is the prevalence of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating?
The estimated prevalence of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating is approximately 5.0 per 100,000 population.
Deep-dive into Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis